286 related articles for article (PubMed ID: 31324226)
21. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients.
Chaves Tdo S; Lopes MH; de Souza VA; Dos Santos Sde S; Pereira LM; Reis AD; David-Neto E
Pediatr Transplant; 2005 Apr; 9(2):192-6. PubMed ID: 15787792
[TBL] [Abstract][Full Text] [Related]
22. Seroprevalence of varicella-zoster virus antibody and immunogenicity of live attenuated varicella vaccine in healthcare workers in Taiwan.
Chong CH; Liu CE; Leong YY; Liao SY; Lai HW; Lee YL
J Microbiol Immunol Infect; 2023 Apr; 56(2):274-281. PubMed ID: 36243667
[TBL] [Abstract][Full Text] [Related]
23. Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.
Perciani CT; Sekhon M; Hundal S; Farah B; Ostrowski MA; Anzala AO; McKinnon LR; Jaoko W; MacDonald KS;
J Infect Dis; 2018 Sep; 218(8):1210-1218. PubMed ID: 29800309
[TBL] [Abstract][Full Text] [Related]
24. Seroepidemiology of varicella-zoster virus infection in a cosmopolitan city (Erzurum) in the eastern Turkey.
Alp H; Altinkaynak S; Ertekin V; Kiliçaslan B; Giiraksin A
Health Policy; 2005 Apr; 72(1):119-24. PubMed ID: 15760704
[TBL] [Abstract][Full Text] [Related]
25. Seroprevalence of varicella-zoster virus in Polish population.
Siennicka J; Trzcińska A; Rosińska M; Litwińska B
Przegl Epidemiol; 2009; 63(4):495-9. PubMed ID: 20120946
[TBL] [Abstract][Full Text] [Related]
26. Seroprevalences of varicella-zoster virus, herpes simplex virus and cytomegalovirus in a cross-sectional study in Mexico.
Conde-Glez C; Lazcano-Ponce E; Rojas R; DeAntonio R; Romano-Mazzotti L; Cervantes Y; Ortega-Barria E
Vaccine; 2013 Oct; 31(44):5067-74. PubMed ID: 24021305
[TBL] [Abstract][Full Text] [Related]
27. A seroepidemiologic survey of the prevalence of varicella-zoster virus in the pediatric population in two university hospitals in Brazil.
Semenovitch I; Lupi O
Int J Dermatol; 2003 Mar; 42(3):193-6. PubMed ID: 12653913
[TBL] [Abstract][Full Text] [Related]
28. Varicella breakthrough infection and effectiveness of 2-dose varicella vaccine in China.
Pan X; Shu M; Ma R; Fang T; Dong H; Sun Y; Xu G
Vaccine; 2018 Sep; 36(37):5665-5670. PubMed ID: 30104113
[TBL] [Abstract][Full Text] [Related]
29. High varicella zoster virus susceptibility in Caribbean island populations: Implications for vaccination.
Vos RA; Mollema L; van Boven M; van Lier A; Smits G; Janga-Jansen AVA; Baboe-Kalpoe S; Hulshof K; Stienstra Y; van der Klis FRM; de Melker HE
Int J Infect Dis; 2020 May; 94():16-24. PubMed ID: 32112964
[TBL] [Abstract][Full Text] [Related]
30. Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland.
Koskiniemi M; Lappalainen M; Schmid DS; Rubtcova E; Loparev VN
Clin Vaccine Immunol; 2007 Sep; 14(9):1057-61. PubMed ID: 17626161
[TBL] [Abstract][Full Text] [Related]
31. Seroepidemiology of varicella in Hangzhou, China in the vaccine era.
Xu Y; Liu S; Che X; Liu Y; Zhang X; Du J; Zhang X; Wang J; Xu E
Hum Vaccin Immunother; 2018; 14(10):2464-2471. PubMed ID: 30019992
[TBL] [Abstract][Full Text] [Related]
32. Seroprevalence of Varicella-Zoster virus IgG antibodies in Swiss children during the first 16 months of age.
Heininger U; Desgrandchamps D; Schaad UB
Vaccine; 2006 Apr; 24(16):3258-60. PubMed ID: 16459000
[TBL] [Abstract][Full Text] [Related]
33. Low Varicella Zoster Virus Seroprevalence Among Young Children in the Democratic Republic of the Congo.
Doshi RH; Alfonso VH; Mukadi P; Hoff NA; Gerber S; Bwaka A; Higgins SG; Sinai C; Cowell B; Ngoie Mwamba G; Okitolonda E; Muyembe-Tamfum JJ; Rimoin AW
Pediatr Infect Dis J; 2018 Feb; 37(2):138-143. PubMed ID: 28834954
[TBL] [Abstract][Full Text] [Related]
34. Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines.
Cohen DI; Davidovici BB; Smetana Z; Balicer RD; Klement E; Mendelson E; Green MS
Infection; 2006 Aug; 34(4):208-13. PubMed ID: 16896579
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
[TBL] [Abstract][Full Text] [Related]
37. Seroprevalence of varicella-zoster virus in Korea.
Choi WS; Noh JY; Huh JY; Jo YM; Lee J; Song JY; Kim WJ; Cheong HJ
J Med Virol; 2010 Dec; 82(12):2123-6. PubMed ID: 20981803
[TBL] [Abstract][Full Text] [Related]
38. [Possibility of prevention of herpes zoster by use of varicella vaccine].
Kawano S; Terada K; Yagi Y; Kataoka N
Kansenshogaku Zasshi; 1998 Jul; 72(7):714-9. PubMed ID: 9745221
[TBL] [Abstract][Full Text] [Related]
39. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
Lopez AS; Guris D; Zimmerman L; Gladden L; Moore T; Haselow DT; Loparev VN; Schmid DS; Jumaan AO; Snow SL
Pediatrics; 2006 Jun; 117(6):e1070-7. PubMed ID: 16740809
[TBL] [Abstract][Full Text] [Related]
40. Varicella seroprevalence in Turkish population in Cyprus.
Kurugol Z; Koturoglu G; Aksit S; Ozacar T
Acta Paediatr; 2007 Jun; 96(6):861-3. PubMed ID: 17465984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
